Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
CRIS > SEC Filings for CRIS > Form 8-K on 6-Nov-2013All Recent SEC Filings

Show all filings for CURIS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for CURIS INC


6-Nov-2013

Results of Operations and Financial Condition, Other Events, Financial Statements and E


Item 2.02. Results of Operations and Financial Condition.

On November 6, 2013, Curis, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2013. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.



Item 8.01. Other Events.

On November 6, 2013, the Company also announced, pursuant to the press release referenced in Item 2.02 to this Current Report on Form 8-K, that it had received written notification from the United States Food and Drug Administration (the "FDA") that its Phase 1 study of CUDC-427 had been placed on partial clinical hold following the report of death in a patient who progressed to liver failure approximately one month following the discontinuation of CUDC-427 dosing. Under this partial clinical hold, new patients may not be enrolled in the study until the Company provides the FDA with required additional information and the FDA notifies the Company that it may re-initiate the study based on its review of the submitted information. The FDA requested the Company provide additional data and analysis on patients in the study and a proposed protocol amendment to mitigate toxicity risk. In the coming weeks, the Company expects to respond to the FDA's requests for additional information and also expects to submit an amendment to the current protocol.



Item 9.01. Financial Statements and Exhibits.

(d)

The Exhibit to this Current Report on Form 8-K is listed in the Exhibit Index attached hereto.


  Add CRIS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for CRIS - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.